Addus HomeCare (NASDAQ:ADUS) Posts Earnings Results, Beats Estimates By $0.10 EPS

Key Points

• EPS of $1.62 beat estimates by $0.10, but revenue came in slightly under consensus at $363.5M versus $366.41M; the quarter showed a net margin of 6.74% and ROE of 9.84%.
• Shares traded up about 0.6% to $100.12 after the report; the stock carries a market cap of $1.87B and a P/E of 19.22, and analysts' consensus is Moderate Buy with a target of $133.22 amid mixed price‑target revisions.
• Company insiders sold 16,788 shares worth roughly $1.79M over the past quarter, with insiders retaining about 4.50% ownership of the company.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) announced its quarterly earnings results on Monday. The company reported $1.62 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.10, FiscalAI reports. Addus HomeCare had a net margin of 6.74% and a return on equity of 9.84%. The firm had revenue of $363.50 million during the quarter, compared to the consensus estimate of $366.41 million.

Addus HomeCare Trading Up 0.6%

NASDAQ ADUS traded up $0.56 during trading on Monday, hitting $100.12. The stock had a trading volume of 387,357 shares, compared to its average volume of 238,113. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.80 and a current ratio of 1.80. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of 19.22, a P/E/G ratio of 1.37 and a beta of 0.92. Addus HomeCare has a one year low of $90.89 and a one year high of $124.43. The stock has a 50 day simple moving average of $98.77 and a 200 day simple moving average of $107.81.

Analyst Ratings Changes

A number of brokerages recently commented on ADUS. Barclays lowered their price target on shares of Addus HomeCare from $112.00 to $102.00 and set an "underweight" rating for the company in a report on Wednesday, March 25th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $139.00 price target on shares of Addus HomeCare in a report on Wednesday, February 25th. Stephens lowered their price target on shares of Addus HomeCare from $140.00 to $135.00 and set an "overweight" rating for the company in a report on Wednesday, February 25th. KeyCorp reaffirmed an "overweight" rating on shares of Addus HomeCare in a report on Wednesday, February 25th. Finally, Truist Financial set a $135.00 price target on shares of Addus HomeCare and gave the company a "buy" rating in a report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $133.22.

Insiders Place Their Bets

In other Addus HomeCare news, EVP Sean Gaffney sold 442 shares of the firm's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $105.36, for a total value of $46,569.12. Following the completion of the sale, the executive vice president owned 20,080 shares of the company's stock, valued at $2,115,628.80. This trade represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael D. Wattenbarger sold 300 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $105.36, for a total transaction of $31,608.00. Following the completion of the sale, the executive vice president directly owned 9,444 shares of the company's stock, valued at approximately $995,019.84. The trade was a 3.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 16,788 shares of company stock valued at $1,785,633 over the last quarter. Corporate insiders own 4.50% of the company's stock.

Hedge Funds Weigh In On Addus HomeCare

Institutional investors have recently modified their holdings of the stock. Global Retirement Partners LLC increased its position in shares of Addus HomeCare by 395.7% during the fourth quarter. Global Retirement Partners LLC now owns 233 shares of the company's stock worth $25,000 after acquiring an additional 186 shares during the period. Larson Financial Group LLC increased its position in shares of Addus HomeCare by 133.3% during the third quarter. Larson Financial Group LLC now owns 238 shares of the company's stock worth $28,000 after acquiring an additional 136 shares during the period. Acumen Wealth Advisors LLC purchased a new position in shares of Addus HomeCare during the fourth quarter worth approximately $29,000. Arax Advisory Partners increased its position in shares of Addus HomeCare by 95.8% during the fourth quarter. Arax Advisory Partners now owns 280 shares of the company's stock worth $30,000 after acquiring an additional 137 shares during the period. Finally, Wexford Capital LP purchased a new position in shares of Addus HomeCare during the third quarter worth approximately $41,000. 95.35% of the stock is owned by hedge funds and other institutional investors.

Addus HomeCare Company Profile

Addus HomeCare NASDAQ: ADUS is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients' independence and quality of life.

The company's core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.